NARD "WILLING TO WORK" WITH DRUG INDUSTRY, BUT MAY HAVE TO "GIVE UP" SOME INDEPENDENCE TO FURTHER PATIENT CARE; ASSOCIATION CHANGES NAME TO NACP
The NARD leadership is seeking to improve its relationship with the pharmaceutical industry in order to advance pharmacy-based patient care programs, NARD Exec VP Calvin Anthony told the independent retail pharmacy association annual meeting Oct. 13 in New Orleans.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth